Floatz logo

m3814

Chronic Lymphocytic Leukemia

Merck KGaA, Darmstadt, GermanyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

144 Active assets in the Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Zofran
Dizal Pharmaceuticals
Phase 4BB
Bendamustine
Dizal Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →